Association between the composite CRP–TyG index and incident malignancy risk in hospitalized patients with diabetes: a retrospective cohort study with nonlinear effect analysis - Report - MDSpire
Advertisement
Association between the composite CRP–TyG index and incident malignancy risk in hospitalized patients with diabetes: a retrospective cohort study with nonlinear effect analysis
Link Between the Combined CRP–TyG Index and Cancer Risk in Hospitalized Diabetic Patients
Overview
This study identifies a significant association between the CRP–TyG index and the risk of incident malignancies in hospitalized diabetic patients. A nonlinear relationship was observed, indicating that higher CRP–TyG levels correlate with increased cancer risk, particularly for gastrointestinal cancers.
Background
Diabetes mellitus is a recognized risk factor for various malignancies, attributed to chronic inflammation and insulin resistance. The CRP–TyG index combines inflammatory and metabolic markers, potentially enhancing cancer risk assessment in hospitalized diabetic patients. Understanding this association is crucial for early identification and management of cancer risk in this vulnerable population.
Data Highlights
CRP–TyG Quartile
Hazard Ratio (HR)
95% Confidence Interval (CI)
Highest
1.92
1.42–2.60
Key Findings
The study included 5,500 hospitalized diabetic patients.
A total of 344 incident malignancies were documented during follow-up.
Malignancy risk increased progressively across CRP–TyG quartiles.
The highest quartile of CRP–TyG showed a significantly elevated risk of malignancy (HR = 1.92).
A nonlinear association was identified with an inflection point at a CRP–TyG z-score of 0.62.
The composite index outperformed CRP or TyG alone in predicting cancer risk.
Clinical Implications
The CRP–TyG index may serve as a valuable biomarker for early malignancy risk stratification in hospitalized diabetic patients. Clinicians should consider integrating this index into routine assessments to identify high-risk individuals and tailor cancer screening strategies accordingly.
Conclusion
The CRP–TyG composite index is independently associated with increased cancer risk in hospitalized patients with diabetes, highlighting its potential role in enhancing cancer risk stratification in clinical practice.
In a Danish phase II trial (RESET-C) reported in the Journal of Clinical Oncology, Gögenur et al found that a single cycle of neoadjuvant pembrolizumab was associated with pathologic complete response...
Investigators have found that overdiagnosis of prostate cancer through prostate-specific antigen screening is low in younger men—but rises sharply with age.
On May 15, 2026, the U.S. Food and Drug Administration (FDA) approved fam-trastuzumab deruxtecan-nxki (Enhertu) for two separate indications for the treatment of adult patients with HER2-positive earl...
